Colin Buss assists the firm in biotechnology patent prosecution. He has extensive knowledge in the areas of immune cell profiling, nanoparticle characterization, primary cell isolation, RNAi, gene cloning, immunochemistry and animal models of infectious disease and cancer. 

Prior to joining Wolf Greenfield, Colin was a graduate research assistant at MIT. His research focused on diagnostic nanotechnology and immunotherapy nanotechnology. He concentrated on adapting nanoparticle technologies for the diagnosis, treatment and monitoring of disease, with applications in Gram-negative bacterial pneumonia, breast cancer, colon cancer and melanoma, including extensive work in immunotherapy. 

Colin received his PhD in Medical Engineering and Medical Physics from the Harvard-MIT Health Sciences and Technology program. He is also co-author of a patent.

  • Biomedical Engineering Society
  • American Institute of Chemical Engineers
  • NSF Graduate Research Fellowship, National Science Foundation


  • CG Buss, Bhatia, SN. “Nanoparticle immunotherapy formulations enhance checkpoint inhibitor responses viamacrophage activation.” (in preparation)
  • CG Buss† , Dudani, JS†, Akana, RTK, Fleming, HE, Bhatia, SN. “Protease activity sensors noninvasively classify bacterial infections and antibiotic responses.” EBioMedicine 38: 248-256 (2018). doi:10.1016/j.ebiom.2018.11.031
  • SR Viswanathan, Nogueira, MF†, Buss, CG†, Krill-Burger, JM, Wawer, MJ, Malolepsza, E, Berger, AC, Choi,PS, Shih, J, Taylor, AM, Tanenbaum, B, Pedamallu, CS, Cherniack, AD, Tamayo, P, Strathdee, CA, Lage, K,Carr, SA, Schenone, M, Bhatia, SN, Vazquez, F, Tsherniak, A, Hahn, WC, Meyerson, M, “Genome-scaleanalysis identifies paralog lethality as a vulnerability of chromosome 1p loss in cancer.” Nature Genetics 50(7):937-943 (2018). doi:10.1038/s41588-018-0155-3
  • JS Dudani, Buss, CG, Akana, RTK, Kwong, GA, Bhatia, SN, “Sustained‐Release Synthetic Biomarkers forMonitoring Thrombosis and Inflammation Using Point‐of‐Care Compatible Readouts.” Advanced FunctionalMaterials 26(17): 2919-2928 (2016). doi:10.1002/adfm.201505142H Goodarzi, Zhang, S, Buss, CG, Fish, L, Tavazoie, S, Tavazoie, SF, “Metastasis-suppressor transcriptdestabilization through TARBP2 binding of mRNA hairpins”, Nature 513: 256-260 (2014).doi:10.1038/nature13466
  • N Pencheva†, Buss, CG†, Posada, J, Merghoub, T, Tavazoie, SF, “Broad-Spectrum Therapeutic Suppression ofMetastatic Melanoma through Nuclear Hormone Receptor Activation.” Cell 156(5): 986-1001 (2014).doi:10.1016/j.cell.2014.01.038
  • N Pencheva, Tran, H†, Buss, CG†, Huh, D, Drobnjak, M, Busam, K, Tavazoie, SF, “Convergent multi-miRNATargeting of ApoE Drives LRP1/LRP8-Dependent MelanomaMetastasis and Angiogenesis.” Cell 151(5): 1068-1082 (2012).doi:10.1016/j.cell.2012.10.028

Expand All

Colin Buss assists the firm in biotechnology patent prosecution. He has extensive knowledge in the areas of immune cell profiling, nanoparticle characterization, primary cell isolation, RNAi, gene cloning, immunochemistry and animal models of infectious disease and cancer. 

Prior to joining Wolf Greenfield, Colin was a graduate research assistant at MIT. His research focused on diagnostic nanotechnology and immunotherapy nanotechnology. He concentrated on adapting nanoparticle technologies for the diagnosis, treatment and monitoring of disease, with applications in Gram-negative bacterial pneumonia, breast cancer, colon cancer and melanoma, including extensive work in immunotherapy. 

Colin received his PhD in Medical Engineering and Medical Physics from the Harvard-MIT Health Sciences and Technology program. He is also co-author of a patent.

  • Biomedical Engineering Society
  • American Institute of Chemical Engineers
  • NSF Graduate Research Fellowship, National Science Foundation
  • CG Buss, Bhatia, SN. “Nanoparticle immunotherapy formulations enhance checkpoint inhibitor responses viamacrophage activation.” (in preparation)
  • CG Buss† , Dudani, JS†, Akana, RTK, Fleming, HE, Bhatia, SN. “Protease activity sensors noninvasively classify bacterial infections and antibiotic responses.” EBioMedicine 38: 248-256 (2018). doi:10.1016/j.ebiom.2018.11.031
  • SR Viswanathan, Nogueira, MF†, Buss, CG†, Krill-Burger, JM, Wawer, MJ, Malolepsza, E, Berger, AC, Choi,PS, Shih, J, Taylor, AM, Tanenbaum, B, Pedamallu, CS, Cherniack, AD, Tamayo, P, Strathdee, CA, Lage, K,Carr, SA, Schenone, M, Bhatia, SN, Vazquez, F, Tsherniak, A, Hahn, WC, Meyerson, M, “Genome-scaleanalysis identifies paralog lethality as a vulnerability of chromosome 1p loss in cancer.” Nature Genetics 50(7):937-943 (2018). doi:10.1038/s41588-018-0155-3
  • JS Dudani, Buss, CG, Akana, RTK, Kwong, GA, Bhatia, SN, “Sustained‐Release Synthetic Biomarkers forMonitoring Thrombosis and Inflammation Using Point‐of‐Care Compatible Readouts.” Advanced FunctionalMaterials 26(17): 2919-2928 (2016). doi:10.1002/adfm.201505142H Goodarzi, Zhang, S, Buss, CG, Fish, L, Tavazoie, S, Tavazoie, SF, “Metastasis-suppressor transcriptdestabilization through TARBP2 binding of mRNA hairpins”, Nature 513: 256-260 (2014).doi:10.1038/nature13466
  • N Pencheva†, Buss, CG†, Posada, J, Merghoub, T, Tavazoie, SF, “Broad-Spectrum Therapeutic Suppression ofMetastatic Melanoma through Nuclear Hormone Receptor Activation.” Cell 156(5): 986-1001 (2014).doi:10.1016/j.cell.2014.01.038
  • N Pencheva, Tran, H†, Buss, CG†, Huh, D, Drobnjak, M, Busam, K, Tavazoie, SF, “Convergent multi-miRNATargeting of ApoE Drives LRP1/LRP8-Dependent MelanomaMetastasis and Angiogenesis.” Cell 151(5): 1068-1082 (2012).doi:10.1016/j.cell.2012.10.028